23522-20-5 Usage
Description
3-(3,4-Dimethoxyphenethyl)-2-thioxo-4-thiazolidinone is a chemical compound with a unique structure that features a thiazolidinone ring and a dimethoxyphenethyl side chain. 3-(3,4-Dimethoxyphenethyl)-2-thioxo-4-thiazolidinone has potential applications in the pharmaceutical industry due to its ability to inhibit tumor necrosis factor, a key player in inflammation and immune response.
Uses
Used in Pharmaceutical Industry:
3-(3,4-Dimethoxyphenethyl)-2-thioxo-4-thiazolidinone is used as a precursor in the preparation of arylmethylene and heterocyclylmethylene thiazolidinediones and analogs. These compounds serve as tumor necrosis factor inhibitors, which can help in managing inflammatory conditions and immune-related disorders.
In the development of these inhibitors, 3-(3,4-Dimethoxyphenethyl)-2-thioxo-4-thiazolidinone plays a crucial role in the synthesis process, enabling the creation of effective therapeutic agents that can target and modulate the activity of tumor necrosis factor. This, in turn, can lead to improved treatment options for various diseases where this cytokine plays a significant role in their progression.
Check Digit Verification of cas no
The CAS Registry Mumber 23522-20-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,3,5,2 and 2 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 23522-20:
(7*2)+(6*3)+(5*5)+(4*2)+(3*2)+(2*2)+(1*0)=75
75 % 10 = 5
So 23522-20-5 is a valid CAS Registry Number.
InChI:InChI=1/C13H15NO3S2/c1-16-10-4-3-9(7-11(10)17-2)5-6-14-12(15)8-19-13(14)18/h3-4,7H,5-6,8H2,1-2H3
23522-20-5Relevant articles and documents
USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS
-
Page/Page column 14, (2008/06/13)
The invention relates to the use of compounds of general formula (I), in which R1, R2 and X are as defined in the description for the preparation of pharmaceutical compositions for the treatment of pathologies in which inhibition of the interaction between HIF-1α and p300 is beneficial, in particular as antiangiogenic medicaments for the therapy of solid tumors.